10 – 13 october 2012 lyon, france · 2020-05-06 · scienti c programme scienti c programme...

www.ectrims.eu/2012

28TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH

IN MULTIPLE SCLEROSIS

10 – 13 OCTOBER 2012LYON, FRANCE

FINAL PROGRAMME

26773_ECTRIMS12_FP_001_ 9.7.2012 8:21 Uhr Seite I

21

Scientific ProgrammeWednesday, 10 October 2012

Teaching Course 1 Auditorium Pasteur

08.30 –10.00 Meet the Professors: A case-based approach to diagnosis and management of MS Chairs: A. Miller (New York, US)

D. Bates (Newcastle, UK)

1 A case-based approach to diagnosis and management of MSA. Miller (New York, US) D. Bates (Newcastle, UK)

Teaching Course 2 Salle Rhône 3

08.30 –10.00 Body fluid biomarkers Chairs: C. Teunissen (Amsterdam, NL)

J. Kuhle (Basel, CH)

2 Basic introduction on biomarkers in body fluids C. Teunissen (Amsterdam, NL)

3 Biomarkers in MS. State of the artJ. Kuhle (Basel, CH)

4 Future use of biomarkers in daily clinical practiceF. Sellebjerg (Copenhagen, DK)

Teaching Course 3 Amphitheatre

08.30 –10.00 Disease-modifying therapy in MS – current and emerging treatmentChairs: H. Wiendl (Münster, DE)

C. Lubetzki (Paris, FR)

5 First-line therapies (ABCR drugs)H. Wiendl (Münster, DE)

6 Monoclonal antibodiesC. Lubetzki (Paris, FR)

7 Oral drugsL. Kappos (Basel, CH)

Scie

ntifi

c Pr

ogra

mm

e

22


Teaching Course 4 Forum 2 & 3

08.30 –10.00 Neuroinflammation, neurodegeneration, and tissue repair – in RRMS, SPMS, PPMSChairs: W. Brück (Göttingen, DE)

C. Lucchinetti (Rochester, US)

8 The normal-appearing brain in MS N. Schaeren-Wiemers (Basel, CH)

9 Neuroinflammation in the cortexC. Lucchinetti (Rochester, US)

10 Inflammation and degeneration in MS W. Brück (Göttingen, DE)

Teaching Course 5 Salon Pasteur

08.30 – 10.00 Quantitating tissue and functional changes in MS

Chairs: M. Filippi (Milan, IT) A. Rovira (Barcelona, ES)

11 Monitoring MS lesion evolutionA. Rovira (Barcelona, ES)

12 Fibre tracts and functionalityO. Ciccarelli (London, UK)

13 Resting state fMRIM. Filippi (Milan, IT)

23


Teaching Course 6 Auditorium Lumière

08.30 – 10.00 From dreams to reality: antigen-specific and stem cell therapy in MS?Chairs: K. Selmaj (Lodz, PL)

A. Uccelli (Genoa, IT)

14 Antigen specific therapy of MSK. Selmaj (Lodz, PL)

15 Autologous mesenchymal stem cells for the treatment of MSA. Uccelli (Genoa, IT)

16 Autologous haematopoetic stem cells for the treatment of MSD. Karussis (Jerusalem, IL)


08.30 – 10.00 Molecular mechanisms of tissue injury in MS lesionsChairs: H. Lassmann (Vienna, AT)

J. van Horssen (Amsterdam, NL)

17 The role of T-cells in MS pathogenesisR. Liblau (Toulouse, FR)

18 Interplay of free radicals and mitochondrial dysfunction in MSJ. van Horssen (Amsterdam, NL)

19 Amplification of oxidative damage in MS brain by ironH. Lassmann (Vienna, AT)

10.00 – 10.30 Coffee Break

Scie

ntifi

c Pr

ogra

mm

e

24


Teaching Course 8 Auditorium Pasteur

10.30 – 12.00 Issues in MS clinical trials: study design and results interpretationChairs: M.P. Sormani (Genoa, IT)

F. Lublin (New York, US)

20 Statistical issues and results interpretation in MS clinical trialsM.P. Sormani (Genoa, IT)

21 Outcomes in MS clinical trialsF. Lublin (New York, US)

22 Surrogate outcomes for immunomodulation and neuroprotectionJ. Wolinsky (Houston, US)

Teaching Course 9 Forum 2 & 3

10.30 – 12.00 Paediatric MS Chairs: B. Banwell (Toronto, CA)

C. Hemingway (London, UK)

23 Environmental and genetic factors in paediatric MSB. Banwell (Toronto, CA)

24 Relapse severity, recovery and progression in paediatric MSE. Waubant (San Francisco, US)

25 Acute disseminated encephalomyelitis in children and MSC. Hemingway (London, UK)

25

Scie

ntifi

c Pr

ogra

mm

e


Teaching Course 10 Amphitheatre

10.30 – 12.00 MRI in the diagnosis of MS and related disordersChairs: N. De Stefano (Siena, IT)

M. Wattjes (Amsterdam, NL)

26 Lesion characteristics in MS: brain and spinal cordM. Wattjes (Amsterdam, NL)

27 The “Radiologically Isolated Syndrome‘‘N. De Stefano (Siena, IT)

28 Pitfalls in diagnosing “active MS‘‘C. Enzinger (Graz, AT)

Teaching Course 11 Auditorium Lumière

10.30 – 12.00 NMO: a practical approach Chairs: D. Wingerchuk (Scottsdale, US)

J. Palace (Oxford, UK)

29 Pathogenesis of NMOK. Fujihara (Sendai, JP)

30 NMO diagnostic criteria: are they really so distinct in clincal practice?D.M. Wingerchuk (Scottsdale, US)

31 Treating patients with NMOR. Marignier (Lyon, FR)

26


Teaching Course 12 Salon Pasteur

10.30 – 12.00 Gender differences in MS Chairs: H. Harbo (Oslo, NO)

M. Tintoré (Barcelona, ES)

32 Genetic aspects and gender differences in disease onset and progressionH. Harbo (Oslo, NO)

33 Effects of sex hormones, the menstrual cycle and pregnancy on MSM. Tintoré (Barcelona, ES)

34 Gender differences in the immune system and response to immunotherapyR. Gold (Bochum, DE)

The ECTRIMS Executive Committee would like to thank all those who have submitted a Teaching Course proposal for the ECTRIMS 2012 and therewith helped to build this year’s programme. Also for the ECTRIMS 2013, the committee would like to encourage everyone with an interest in multiple sclerosis to submit a proposal. The proposal should include the following: main title of the course, full names of two organisers, titles of three lectures, full names of proposed lecturers. Please note that accepted proposals may not be integrated exactly as submitted. They may be adapted in order to create an overall balanced programme.

The deadline for submitting proposals is 30 November 2012. Please send them to:

ECTRIMS 2013Administrative Secretariatc/o Congrex Switzerland Ltd.Peter Merian-Strasse 804002 Basel / SwitzerlandE-mail: [email protected]

Call for Teaching Courses

27

Scie

ntifi

c Pr

ogra

mm

e



10.30 – 12.00 Controversies in the natural history of multiple sclerosisChairs: C. Confavreux (Lyon, FR)

A. Scalfari (London, UK)

35 Relapses and long-term disability accumulationA. Scalfari (London, UK)

36 Age, prognosis and the MS disease courseH. Tremlett (Vancouver, CA)

37 Emerging concepts from natural history studies: an overviewC. Confavreux (Lyon, FR)

12.00 – 12.30 Lunch

Parallel Session 14 Amphitheatre

12.30 – 14.00 Late Breaking News 1Chairs: T. Olsson (Stockholm, SE)

D. Laplaud (Nantes, FR)

12.30 The MS-STAT trial: high dose simvastatin 38a demonstrates neuroprotection without

immune-modulation in secondary progressive multiple sclerosis (SPMS) – a phase II trial

J. Chataway, A. Alsanousi, D. Chan, D. MacManus, K. Hunter, J. Foster, C. Bangham, D. Wilkie, J. Nicholas, S. Clegg, C. Nielsen, N. Scheurer, V. Calder, J. Greenwood, C. Frost, R. Nicholas (London, Brighton, UK)

12.45 Induction of immune tolerance by autologous 38b peptide-coupled cells – a phase I trial in

relapsing-remitting and secondary-progressive multiple sclerosis patients

A. Lutterotti, S. Yousef, A. Sputtek, K.H. Stürner, J.-P. Stellmann, P. Breiden, S. Reinhardt, C. Schulze, M. Bester, C. Heesen, S. Schippling, S. Miller, M. Sospedra, R. Martin (Innsbruck, AT; Hamburg, Hamburg-Eppendorf, DE; Zurich, CH; Chicago, US)

28


Forum 2 & 3

14.00 – 15.30 Young Scientific Investigators’ Session IChairs: P. Calabresi (Baltimore, US)

J. de Sèze (Strasbourg, FR)

14.00 Multi-contrast MR imaging at 7T in multiple42 sclerosis: highest lesion detection in cortical

grey matter with 3D fluid-attenuated inversion recovery

I.D. Kilsdonk, W.L. de Graaf, A. Lopez Soriano, J.J. Zwanenburg, F. Visser, J.P.A. Kuijer, J.J.G. Geurts, P.J.W. Pouwels, C.H. Polman, J.A. Castelijns, P.R. Luijten, F. Barkhof, M.P. Wattjes (Amsterdam, Utrecht, NL)

14.15 Neuromyelitis optica spectrum disorder and43 multiple sclerosis can be distinguished on the

basis of MRI brain lesion characteristicsL.A.E. Matthews, R. Marasco, M. Jenkinson, W. Kuker, M.I. Leite, A. Giorgio, N. De Stefano, S. Luppe, N. Robertson, H. Johansen-Berg, N. Evangelou, J. Palace (Oxford, UK)

13.00 Defective sphingosine-1-phosphate receptor 139a (S1PR1) internalization exacerbates autoimmune

neuroinflammation by enhancing Stat3-mediated Th17 polarization

C.S. Garris, S. Acharya, R. Axtell, D. Lewis, R.A. Sobel, L. Steinman, T. Hla, M.H. Han (Stanford, US)

13.15 A novel autoantigen in neuromyelitis optica39b spectrum disorders J.S. Tzartos, C. Stergiou, K. Kilintireas, P. Zisimopoulou,

T. Thomaidis, S.J. Tzartos (Athens, Patras, GR)

13.30 Association of MRI metrics and clinical relapses40a to explain long-term disability changes in

relapsing multiple sclerosis A. Giorgio, M.P. Sormani, M.L. Stromillo, M.L. Bartolozzi,

F. Rossi, M. Battaglini, A. De Leucio, L. Guidi, P. Maritato, E. Portaccio, M.P. Amato, A. Federico, N. De Stefano (Siena, Genoa, Empoli, Florence, IT)

13.45 Gene expression profiling study in multiple 40b sclerosis patients responders and non-responders

to treatment with glatiramer acetate M. Comabella, N. Fissolo, R. Nurtdinov, J. Río, C. Tur,

J. Sastre-Garriga, X. Montalban (Barcelona, ES)

29

Scie

ntifi

c Pr

ogra

mm

e


14.30 Rodent models of neuromyelitis optica44 based on pathogenicity of engineered

anti-aquaporin-4 ‘NMO superantibodies’ with enhanced effector functionsJ. Ratelade, N. Asavapanumas, P. W. Phuan, S. Wemlinger, A. Ritchie, J. L. Bennett, A.S. Verkman (San Francisco, Aurora, US)

14.45 A novel retinal phenotype in multiple sclerosis45 is predictive of inflammatory disease activity

and disability progressionS. Saidha, E. Sotirchos, M. Ibrahim, J. Gelfand, Y. Sepah, J. Ratchford, J. Oh, M. Seigo, S. Newsome, L. Balcer, E. Frohman, C. Crainiceanu, A. Green, Q. Nguyen, P. Calabresi (Baltimore, San Francisco, Philadelphia, Dallas, US)

15.00 Impaired decision-making in MS and grey 46 matter diffusion orientational complexity

N. Muhlert, V. Sethi, M. Ron, L. Cipolotti, G. Parker, H. Haroon, T.A. Yousry, C.A. Wheeler-Kingshott, D.H. Miller, D.T. Chard (London, Manchester, UK)

15.15 Relation of cerebellar volume to performance47 in cognitive tests in patients with multiple

sclerosisK. Weier, I.K. Penner, S. Magon, M. Amann, Y. Naegelin, N. Mueller-Lenke, A. Beck, M. Andelova, T. Derfuss, E.-W. Radue, C. Stippich, L. Kappos, T. Sprenger (Basel, CH; Langenfeld, DE)

15.30 – 16.00 Coffee Break

Forum 2 & 3

16.00 – 17.15 Young Scientific Investigators’ Session IIChairs: J. Stadelmann (Göttingen, DE)

A. Siva (Istanbul, TR)

16.00 Axonal damage in inflammatory demyelinating48 lesions of paediatric patients

S. Pfeifenbring, R.F. Bunyan, I. Metz, C.F. Lucchinetti, W. Brück (Göttingen, DE; Dammam, SA; Rochester, US)

30


16.15 Analysis of HLA classical alleles and derived49 amino acids identifies independent effects in

several DRB1 and non-DRB1 classical allelesN.A. Patsopoulos, L. Barcellos, C. Schaefer, R.Q. Hintzen, P.L. De Jager, P.I.W. de Bakker on behalf of ANZgene, GeneMSA, IMSGC

16.30 Role of the chemokine CCL2 in T-cell tolerance50 and protection from experimental autoimmune

encephalomyelitisO. Cédile, M. Løbner, H. Toft-Hansen, T. Owens (Odense, DK)

16.45 MCAM is expressed by IL-17-producing 51 T-lymphocytes and regulates their entry in the

CNSC. Larochelle, J. Alvarez, H. Kebir, M.-A. Lécuyer, R. Cayrol, O. Saint-Laurent, J. Poirier, P. Duquette, N. Arbour, A. Prat (Montreal, CA)

17.00 Endoplasmatic reticulum stress responses:52 mechanisms of oligodendrocyte stress in the

cuprizone model for multiple sclerosisJ. Goldberg, M. Victor, B. Krauspe, S. Diederichs, S. Amor, P. van der Valk, T. Clarner, C. Beyer, M. Kipp (Aachen, DE; Amsterdam, NL)

Satellite Symposium Amphitheatre

17.15 – 18.15 Get on track, stay on track: patient journeys in MSorganized by Merck Serono S.A.

Chairs: D. Bates (Newcastle upon Tyne, UK) P. Vermersch (Lille, FR)

Patient advocate: N. Blanc (Geneva, CH)

17.15 WelcomeP. Vermersch (Lille, FR)

17.20 Starting on the right track53 M.S. Freedman (Ottawa, CA)

31

Scie

ntifi

c Pr

ogra

mm

e


17.35 Staying the course: benefits of long-term 54 therapy adherence

V. Devonshire (Vancouver, CA)

17.55 Tracking outcomes: new imaging techniques55 P. Gallo (Padua, IT)

18.10 A patient’s perspective N. Blanc (Geneva, CH) and faculty

18.15 CloseD. Bates (Newcastle upon Tyne, UK)


18.30 – 19.30 Growing global experience with once-daily oral fingolimod in MSorganized by Novartis Pharma AG

Chairs: J. Pelletier (Marseille, FR) M. Duddy (Newcastle, UK)

Welcome and introductionJ. Pelletier (Marseille, FR) M. Duddy (Newcastle, UK)

56 Initiating treatment with fingolimod B. Singer (St. Louis, US)

57 Growing evidence for the benefit–risk profile of treatment with fingolimodH.-P. Hartung (Düsseldorf, DE)

58 The evolving role of fingolimod in MS treatment

M. Duddy (Newcastle, UK)

ConclusionsJ. Pelletier (Marseille, FR) M. Duddy (Newcastle, UK)

19.45 Welcome Reception at Les Halles de Lyon – Paul Bocuse

32

Scientific ProgrammeThursday, 11 October 2012

* Invited lecture

Plenary Session 1 Amphitheatre

08.30 – 10.00 Welcome Address and ECTRIMS LectureChairs: M. Clanet (Toulouse, FR)

C. Confavreux (Lyon, FR)

08.30 Welcome to Lyon60 F.-N. Gilly (Lyon, FR)

President of Claude Bernard Lyon 1 University

08.40 Welcome to Lyon C. Confavreux (Lyon, FR)

08.50 The ECTRIMS Society M. Clanet (Toulouse, FR)

09.00 ECTRIMS Lecture:61* Biotherapies in MS: hopes and threats

H.-P. Hartung (Düsseldorf, DE)

10.00 – 10.30 Coffee Break and and Poster Viewing


10.30 – 12.00 From environment to MSChairs: G. Ebers (Oxford, UK)

M. Debouverie (Nancy, FR)

10.30 From infections to MS62* R. Du Pasquier (Lausanne, CH)

10.50 From physico-chemical agents exposure to MS63* S. Ramagopalan (London/Oxford, UK)

11.10 An age at exposure effect in the association64 between sun exposure and the risk of MS in

Norway and Italy. The EnvIMS studyK. Bjørnevik, T. Riise, K. Wesnes, E. Granieri, I. Casetta, J. Drulovic, K.M. Myhr, K. Lauer, M. Kampman, S. Magalhaes, T. Pekmezovic, T. Holmøy, A.M. Landtblom, C. Wolfson, M. Pugliatti (Bergen, Tromsø, Oslo, NO; Ferrara, Sassari, IT; Belgrade, RS; Griesheim, DE; Montreal, CA; Linköping, SE)

33

Scie

ntifi

c Pr

ogra

mm

e


* Invited lecture

11.25 Smoking is a potentially modifiable risk factor65 for all causes of mortality in patients with

multiple sclerosisA. Manouchehrinia, M. Weston, C. Constantinescu (Nottingham, UK)

11.40 Cytomegalovirus seropositivity is associated66 with lower multiple sclerosis risk

E. Sundqvist, T. Bergström, H. Daialhosein, P. Sundström, J. Hillert, L. Alfredsson, I. Kockum, T. Olsson (Stockholm, Gothenburg, Umeå, SE)

Parallel Session 2 Forum 2 & 3

10.30 – 12.00 From genetics to MSChairs: M. Comabella (Barcelona, ES)

B. Fontaine (Paris, FR)

10.30 From the genes to MS67* J.S. Sawcer (Cambridge, UK)

10.50 Expectations from omics in MS68* D. Brassat (Toulouse, FR)

11.10 Genetic differences relating to oligoclonal69 band status in multiple sclerosis

I.-L. Mero, M. W. Gustavsen, H. Sæther, S. Flåm, H.B. Søndergaard, P.E.H. Jensen, T. Berge, A. Bjølgerud, A. Muggerud, J.H. Aarset, K.-M. Myhr, E.G. Celius, F. Sellebjerg, J. Hillert, L. Alfredsson, T. Olsson, A.B. Oturai, I. Kockum, B.A. Lie, B. Kulle, H.F. Harbo (Oslo, Bergen, NO; Copenhagen, DK; Stockholm, SE)

11.25 ICAM3 expression level integrates the effects70 of six MS susceptibility alleles: dissecting a

molecular cascade relevant to MS susceptibilityT. Raj, M. Kuchroo, B. Keenan, L. Ottoboni, X. Hu, S. Raychaudri, P. De Jager (Boston, US)

34


* Invited lecture

11.40 A pharmacogenetic study on Italian, US and71 French MS patients reveals an SLC9A9 variant

as a novel marker of response to interferon-BF. Esposito, E. Lim, M. Romeo, M. Rodegher, M. Sorosina, P. Brambilla, N.A. Patsopoulos, B. Keenan, V. Martinelli, D. Brassat, G. Comi, F. Martinelli Boneschi, P.L. De Jager (Milan, IT; Boston, US; Toulouse, FR)

Parallel Session 3 Auditorium Lumière

10.30 – 12.00 Adaptative and innate immunity in MSChairs: R. Gold (Bochum, DE)

R. Liblau (Toulouse, FR)

10.30 The effects of Vitamin D on the adaptive 72* immune system (T and B cells) in relation to

clinical manifestations in MSR.M. Hupperts, J. Smolders, J. Damoiseaux (Sittard-Geleen, NL)

10.50 Microglia and monocytes: kith or kin?73* R.M. Ransohoff (Cleveland, US)

11.10 The potassium channel KIR4.1 as an immune74 target in multiple sclerosis

R. Srivastava, M. Aslam, R Kalluri, L. Schirmer, D. Buck, B. Tackenberg, V. Rothhammer, A. Chan, R. Gold, A. Berthele, J. Bennett, T. Korn, B. Hemmer (Munich, Marburg, Bochum, DE; Denver, US)

11.25 Immune reconstitution after autologous 75 haematopoietic stem cell transplantation for

aggressive relapsing-remitting MSJ. Burman, J. Fagius, T.H. Tötterman, M. Fransson, S.M. Mangsbo, A.S.I. Loskog (Uppsala, SE)

11.40 Encephalitogenic and non-encephalitogenic76 T-Cell epitopes of aquaporin-4

P. Nelson, M. Varrin-Doyer, C. Spencer, S. Sagan, R. Sobel, J. Bennett, S. Zamvil (San Francisco, Palo Alto, Denver, US)

12.00 – 12.30 Lunch Break and Poster Viewing

35

Scie

ntifi

c Pr

ogra

mm

e


* Invited lecture


12.45 – 13.45 MS pathophysiology and implications for treatmentorganized by Genzyme, a Sanofi Company

Chair: C. Confavreux (Lyon, FR)

12.45 Welcome and introductionC. Confavreux (Lyon, FR)

12.50 Role of lymphocytes in the pathogenesis of MS77 H. Wiendl (Münster, DE)

13.05 MS immunomodulation: experiences with 78 B- & T-lymphocyte targeting agents

G. Comi, G. Giovannoni (Milan, IT; London, UK)

13.35 Questions and panel discussion

36


* Invited lecture


14.00 – 15.30 Neurons and oligodendrocytes in MSChairs: H. Lassmann (Vienna, AT)

P.-O. Couraud (Paris, FR)

14.00 Neurons in MS79* D. Mahad (Edinburgh, UK)

14.20 Oligodendrocytes in MS80* T. Kuhlmann (Münster, DE)

14.40 Differential roles for the small heat shock 81 protein A B-crystallin in cuprizone-induced

de- & remyelinationH.F. Kuipers, J. Yoon, J. Vister, T.D. Palmer, L. Steinman (Stanford, US)

14.55 Early disruption of astrocytic connexins in 82 multiple sclerosis, Baló’s disease and

neuromyelitis opticaK. Masaki, S.O. Suzuki, T. Matsushita, T. Matsuoka, M. Suzuki, T. Suenaga, T. Tabira, T. Iwaki, J. Kira (Fukuoka, Hamamatsu, Tenri, Tokyo, JP)

15.10 Heterogeneity of cortical remyelination in 83 multiple sclerosis

E.M.M. Strijbis, E.J. Kooi, P. van der Valk, C.H. Polman, J.J.G. Geurts (Amsterdam, NL)

37

Scie

ntifi

c Pr

ogra

mm

e


* Invited lecture


14.00 – 15.30 From inflammation to neurodegenerationChairs: W. Brück (Göttingen, DE)

P. Giraudon (Lyon, FR)

14.00 From focal inflammation to neurodegeneration84* F. Zipp (Mainz, DE)

14.20 From diffuse inflammation to 85* neurodegeneration

D. Merkler (Geneva, CH)

14.40 Periplaques form extensive lesions in multiple86 sclerosis spinal cords

A. Lhuillier, M. Chanal, G. Androdias, R. Reynolds, C. Confavreux, S. Nataf (Lyon, FR; London, UK)

14.55 Myelin debris regulates inflammatory 87 responses in an experimental demyelination

animal model and multiple sclerosis lesionsT. Clarner, F. Diederichs, K. Berger, B. Denecke, L. Gan, P. van der Valk, C. Beyer, S. Amor, M. Kipp (Aachen, DE; Amsterdam, NL)

15.10 Preventing neurodegeneration in 88 neuroinflammation – an in vivo two-photon

imaging approachV. Siffrin, R. Gollan, J. Birkenstock, M. Paterka, F. Zipp (Mainz, DE)

38


* Invited lecture


14.00 – 15.30 Biology of recoveryChairs: N. Scolding (Bristol, UK)

S. Chandran (Edinburgh, UK)

14.00 Sodium channels in MS89* J.A. Black (New Haven, US)

14.20 Remyelination90* C. Lubetzki (Paris, FR)

14.40 Dosing regimen impacts in vitro effects of91 FTY720 on human astrocyte proliferation,

IL1b-induced Ca2+ mobilisation, and miRNA-155 expressionC. Wu, C.S. Moore, S. Leong, T.A. Johnson, T.E. Kennedy, P. Séguéla, A. Bar-Or, J.P. Antel (Montreal, CA)

14.55 New enhancers of endogenous remyelination:92 an extensive in vitro and ex vivo screening

C. Eleuteri, C. Veroni, R. Umeton, V. Annibali, G. Ristori, M. Salvetti, C. Agresti (Rome, IT)

15.10 Krüppel-like factor-6 is required for 93 oligodendrocyte maturation and CNS

myelinationL. Asp, E. Kramer, Y.-M. Lee, J. Zhang, X. Pedre, A.T. Argaw, J. Liu, D. Dutta, E. Zaslavsky, D. Braun, T. Pham, G. Narla, C. Raine, P. Casaccia, S. Friedman, G. John (New York, Bronx, US)

Poster Session I Poster Exhibition

15.30 – 17.00 Poster numbers P177 – P635(for details see pages 59 – 107)

39

Scie

ntifi

c Pr

ogra

mm

e


* Invited lecture

Hot Topic 1 Amphitheatre

17.00 – 17.45 Devic‘s neuromyelitis optica spectrumChairs: J. Palace (Oxford, UK)

D. Wingerchuk (Scottsdale, US)

17.00 Immunobiology94* R. Marignier (Lyon, FR)

17.15 CRION/RION95* D. Bichuetti (Sao Paulo, BR)

17.30 Clinical and MR features of paediatric 96 aquaporin-4-IgG seropositive neuromyelitis

optica spectrum disordersS. Tenembaum, S. Pittock, J. Princich, V. Lennon, M. Segura (Buenos Aires, AR; Rochester, US)

Hot Topic 2 Forum 2 & 3

17.00 – 17.45 PML and IRISChairs: T. Weber (Hamburg, DE)

H. Wiendl (Münster, DE)

17.00 The PML spectrum97* D. Clifford (St. Louis, US)

17.15 Epidemiology of natalizumab-associated PML98* and IRIS in MS

P. Vermersch (Lille, FR)

17.30 Imaging findings for PML in 99 natalizumab-treated MS patients

N. Richert, G. Bloomgren, D. Cadavid, T. Dong-Si, S. Richman, B. Ticho (Weston, US)

40


* Invited lecture

Hot Topic 3 Auditorium Lumière

17.00 – 17.45 Temporal changes in MS epidemiologyChairs: P. De Jager (Boston, US)

M. Pugliatti (Sassari, IT)

17.00 Overview100* N. Koch-Henriksen (Aalborg, DK)

17.15 The French OFSEP experience101* T. Moreau (Dijon, FR)

17.30 Increasing multiple sclerosis incidence in 102 Tehran, Iran: a Joinpoint Trend Analysis

P. Heydarpour, K. Mohammad, M.S. Yekaninejad, J. Lotfi, M.A. Sahraian (Tehran, IR)

Satellite Symposium Auditorium Lumière

18.00 – 19.00 MS spasticity symptoms management. Endocannabinoid system modulator data beyond clinical trialsorganized by Almirall

Chair: M. Trojano (Bari, IT)

103 MS spasticity daily management, retrospective data from EUT. Berger (Innsbruck, AT)

104 Endocannabinoid system modulator use in the everyday clinical practice in UK and SpainJ.A. Garcia Merino (Madrid, ES)

105 A new MS spasticity treatment option effect in everyday clinical practice and cost-effectiveness in GermanyP. Flachenecker (Bad Wilbad, DE)

Réservé uniquement aux médecins n’exerçant pas sur le territoire français.

41



19.15 – 20.15 New concepts in MS pathology shed light on MS treatment approachesorganized by Teva Pharmaceutical Industries

Chair: R. Gold (Bochum, DE)

106 Peripheral and central immunomodulation – new insights of glatiramer acetateO. Khan (Detroit, US)

107 MS pathology: from focal to diffuse damageW. Brück (Göttingen, DE)

108 Laquinimod: a new MS therapy with evidence for CNS direct effectG. Comi (Milan, IT)

Scie

ntifi

c Pr

ogra

mm

e

42

Scientific ProgrammeFriday, 12 October 2012

ECTRIMS Council Meeting Salle Rhône 3

07.30 – 09.00 Council members, by invitation only

Free Communications I Amphitheatre

09.15 – 10.15 Platform presentation of selected abstracts on therapy and clinical trialsChairs: J. Wolinsky (Houston, US)

E. Wassmer (Birmingham, UK)

09.15 EDSS changes and progression in the CombiRx109 randomised clinical trial: 3-year results

G. Cutter, S. Cofield, T. Gustafson, R. Conwit, J. Wolinsky, F. Lublin for the The CombiRx Investigators

09.30 Eosinophil pathogenicity in neuromyelitis110 optica by ADCC and CDCC mechanisms:

Potential therapeutic efficacy of over-the-counter eosinophil stabilizing drugsH. Zhang, J. Ratelade, A.S. Verkman (San Francisco, US)

09.45 Statistical properties of time to first relapse as111 an endpoint in multiple sclerosis clinical trials

A. Signori, P. Siri, M.P. Sormani (Genoa, Turin, IT)

10.00 Endovascular treatment of CCSVI in patients112 with multiple sclerosis: clinical outcome of an

Italian cohort of 462 casesA. Ghezzi, P.O. Annovazzi, M.P. Amato, R. Balgera, P. Banfi, M.L. Bartolozzi, R. Bergamaschi, A. Bertolotto, A. Bianchi, A. Bosco, E. Capello, M. Capobianco, R. Capra, P. Cavalla, R. Clerici, G. Coarelli, E. Cocco, N. De Rossi, C. Di Tillio, M.T. Ferrò, A. Gallo, P. Gallo, L. Lamantia, A. Lugaresi, G. Lus, S. Malucchi, L. Moiola, L. Provinciali, F. Patti, P. Perini, P. Perrone, A. Protti, M.E. Rodegher, P. Rossi, M. Rottoli, M. Rovaris, G. Salemi, M. Salvetti, I. Simone, M.R. Tola, M. Trojano, F. Vitetta, M.G. Marrosu, G. Comi and MS Study Group, Italian Society of Neurology

43


* Invited lecture

Free Communications II Forum 2 & 3

09.15 – 10.15 Platform presentation of selected abstracts on MS disease evolutionChairs: J. Hillert (Stockholm, SE)

M. Tintoré (Barcelona, ES)

09.15 Predicting clinical conversion to multiple113 sclerosis in patients with clinically isolated

syndrome using machine learning techniquesO. Ciccarelli, P.P. Kwok, V. Wottschel, D. Chard, M.L. Stromillo, N. De Stefano, A.J. Thompson, D.H. Miller, D.H. Alexander (London, UK; Lübeck, DE; Siena, IT)

09.30 Magnetic resonance phase predicts acute 114 multiple sclerosis lesions

A. Rauscher, V. Wiggermann, E. Hernández Torres, I. Vavasour, C. Laule, W. Moore, D. Li, A. Traboulsee, A. MacKay (Vancouver, CA)

09.45 Topographic analysis of visual-evoked 115 potentials improves sensitivity for previous

optic neuritisM. Hardmeier, F. Hatz, Y. Naegelin, C. Schindler, L. Kappos, M. Seeck, P. Fuhr, C. Michel (Basel, Geneva, CH)

10.00 It’s time to change the way we measure116 change: demonstration, explanation,

recommendationsJ.C. Hobart, S.J. Cano, A.J. Thompson, D. Andrich (Plymouth, UK; Perth, AU)

Scie

ntifi

c Pr

ogra

mm

e

44


Free Communications III Auditorium Lumière

09.15 – 10.15 Platform presentation of selected abstracts on fatigue and cognitionChairs: E. Havrdová (Prague, CZ)

D. Karussis (Jerusalem, IL)

09.15 Computer-assisted rehabilitation of attention117 in patients with multiple sclerosis:

results of a randomised double-blind trialM.P. Amato, B. Goretti, E. Portaccio, R.G. Viterbo, P. Iaffaldano, M. Trojano (Florence, Bari, IT)

09.30 Fatigue in multiple sclerosis: relation to 118 quantitative neurologic and visual outcomes

S. Chahin, D. Miller, R. Sakai, J. Wilson, A. Green, P. Calabresi, E. Frohman, S. Galetta, L. Balcer (Philadelphia, Cleveland, San Francisco, Baltimore, Dallas, US)

09.45 Relationship between cognition and working119 hours in people with clinically isolated

syndrome and early relapsing-remitting multiple sclerosisP. Jongen, K. Wesnes, B. Van Geel, P. Pop, E. Sanders, H. Schrijver, L. Visser, J. Gilhuis, O. Sinnige, A. Brands (Nijmegen, Alkmaar, Venray, Breda, Hoorn, Tilburg, Delft, Leeuwarden, Utrecht, NL; Goring, UK)

10.00 Grey matter damage predicts the accumulation120 of disability and cognitive impairment 13 years

later in patients with multiple sclerosisM. Filippi, P. Preziosa, M. Copetti, G. Riccitelli, M.A. Horsfield, V. Martinelli, G. Comi, M.A. Rocca (Milan, San Giovanni Rotondo (FG), IT; Leicester, UK)

10.15 – 10.45 Coffee Break & Poster Viewing

45

Scie

ntifi

c Pr

ogra

mm

e


* Invited lecture


10.45 – 12.15 Beyond clinical monitoring of progression in MSChairs: C. Pozzilli (Rome, IT)

F. Cotton (Lyon, FR)

10.45 Biological markers121* A. Petzold (Amsterdam, NL)

11.05 MR and OCT markers122* D. Miller (London, UK)

11.25 Retinal atrophy and brain damage in MS: 123 a model for trans-synaptic neuronal

degeneration?I. Gabilondo, A. Saiz, E. Martinez, E. Fraga, S. Llufriu, S. Ortiz, C. Falcon, J. Berenguer, N. Sola, M. Sepulveda, Y. Blanco, F. Graus, B. Sanchez-Dalmau, P. Villoslada (Barcelona, ES)

11.40 Mechanisms of disability in relapse onset 124 multiple sclerosis of long disease duration

H. Kearney, M.A. Rocca, L. Balk, J. Sastre-Garriga, J. Reinhardt, S. Ruggieri, A. Rovira, L. Kappos, M. Rovaris, C. Gasperini, X. Montalban, J.J.G. Geurts, F. Barkhof, M. Filippi, D.R. Altmann, O. Ciccarelli, D.H. Miller, D.T. Chard on behalf of the MAGNIMS collaborative group

11.55 Probing the clinico-radiological paradox125 of the spinal cord in multiple sclerosis with

quantitative MRIJ. Oh, S. Saidha, M. Chen, S. Smith, J. Prince, C. Jones, P. van Zijl, D. Reich, P. Calabresi (Baltimore, US)

46


* Invited lecture


10.45 – 12.15 From natural to treated historyChairs: J. Rio (Barcelona, ES)

P. Soelberg Sørensen (Copenhagen, DK)

10.45 Standpoint of the neurologist126* C. Confavreux (Lyon, FR)

11.05 From natural to treated history – standpoint of127* the methodologist

M.P. Sormani (Genoa, IT)

11.25 Do all patients with multiple sclerosis 128 ultimately develop progressive MS?

M. Tutuncu, J. Tang, N. Abou Zeid, N. Kale, D. Crusan, E. Atkinson, A. Siva, S. Pittock, I. Pirko, M. Keegan, C. Lucchinetti, J. Noseworthy, M. Rodriguez, B. Weinshenker, O. Kantarci (Istanbul, TR; Minneapolis, Rochester, US; Beirut, LB)

11.40 Relation of long-term exposure to 129 subcutaneous interferon-B-1a with clinical

outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS-15 studyL. Kappos, P. Cornelisse, L. Lehr, J. Kuhle, B. Uitdehaag (Basel, Geneva, CH; Amsterdam, NL)

11.55 Cognitive issues in childhood and juvenile 130 multiple sclerosis patients: five-year results

M.P. Amato, B. Goretti, A. Ghezzi, S. Lori, B. Hakiki, M. Giannini, L. Pastò, L. Razzolini, L. Moiola, M. Falautano, R.G. Viterbo, F. Patti, S. Cilia, C. Pozzilli, V. Bianchi, M. Roscio, V. Martinelli, G. Comi, E. Portaccio, M. Trojano on behalf of the MS Study Group of the Italian Neurological Society

47

Scie

ntifi

c Pr

ogra

mm

e


* Invited lecture


10.45 – 12.15 From databases and cohorts to pharmaco-epidemiologyChairs: M. Trojano (Bari, IT)

M. Clanet (Toulouse, FR)

10.45 Pharmaco-epidemiology: methodological 131* aspects

G. Tognoni (Santa Maria Imbaro (Chieti), IT)

11.05 The example of MS132* S. Vukusic (Lyon, FR)

11.25 Comparison of natalizumab and 133 interferon-B/glatiramer efficacy using

propensity-matched registry dataT. Spelman, F. Pellegrini, A. Zhang, R. Hyde, A. Pace, R. Arnold, M. Trojano, H. Wiendl, L. Kappos, S. Belachew, F. Verheul, F. Grand‘Maison, G. Izquierdo, H. Butzkueven on behalf of the MSCOMET Investigators (an MSBase Substudy) and the TOP investigators

11.40 The SURVIMUS study, a large multicentre study134 on long-term mortality of multiple sclerosis

patients in FranceE. Leray, S. Vukusic, C. Confavreux, M. Debouverie, M. Clanet, B. Brochet, J. de Sèze, H. Zéphir, P. Vermersch, C. Lebrun-Frenay, G. Defer, T. Moreau, P. Clavelou, J. Pelletier, L. Rumbach, P. Cabre, J.P. Camdessanché, J. Yaouanq, E. Le Page, G. Edan (Rennes, Lyon, Nancy, Toulouse, Bordeaux, Strasbourg, Lille, Nice, Caen, Dijon, Clermont-Ferrand, Marseille, Besançon, Fort de France, Saint-Etienne, FR)

11.55 The natural history of aggressive multiple 135 sclerosis: findings from British Columbia, Canada

S. Menon, F. Zhu, A. Shirani, J. Oger, A. Traboulsee, M. Freedman, BC. MS Clinic Neurologists, H. Tremlett (Vancouver, Ottawa, CA)

12.15 – 12.45 Lunch and Poster Viewing

48


Satellite Symposium Forum 2 & 3

12.45 – 13.45 Novel performance measures for early and long-term gainsorganized by Bayer HealthCare

Chair: P. Vermersch (Lille, FR)

Opening remarksP. Vermersch (Lille, FR)

136 Historical measures of response and outcomesT. Ziemssen (Dresden, DE)

137 Novel measures broadening our understanding of treatment benefits and risksX. Montalban (Barcelona, ES)

138 The ultimate long-term measure – survivalA. Reder (Chicago, US)

Q&A / Closing remarksP. Vermersch (Lille, FR)

49

Scie

ntifi

c Pr

ogra

mm

e


* Invited lecture


14.00 – 15.30 PregnancyChairs: J. Nogales (Santiago, CL)

H. Tremlett (Vancouver, CA)

14.00 Prognosis – Pregnancy139* M.P. Amato (Florence, IT)

14.20 MS treatments during pregnancy140* E. Waubant (San Francisco, US)

14.40 Pregnancy outcomes from fingolimod clinical141 trials and post-marketing experience and the

need for a multinational Gilenya™ (fingolimod) Pregnancy Exposure Registry in multiple sclerosisY. Geissbühler, H. Butzkueven, S. Hernández-Diaz, K. Hellwig, G. Koren, T. MacDonald, H. Tilson, K. Starzyk, E. Plana, M. Cremer, P. von Rosenstiel, D. Anand, V. Dong, R. Schlosshauer, X. Zhang (Basel, CH; Parkville, AU; Boston, Chapel Hill, Cambridge, East Hanover, US; Bochum, DE; Toronto, CA; Dundee, UK; Barcelona, ES)

14.55 Evidence for microRNA-mediated regulation142 during pregnancy: miR183 and miR9-2 make up

a negative feedback loop to control inflammation through the interaction with the effectors Nurr1 and SOCS2F. Gilli, N. Navone, S. Perga, S. Martire, C. Cosentino, C. Barlassina, M. Arigoni, R. Calogero, A. Bertolotto (Orbassano, Milan, Turin, IT)

15.10 The POPARTMUS French-Italian multicentric143 trial of Post Partum Progestin and Estriol in

Multiple Sclerosis: final resultsS. Vukusic, M. El-Etr, I. Ionescu, F. Cotton, H. Merle, C. Cornu, B. Frangoulis, L. Remontet, N. Bossard, L. Durelli, E.E. Baulieu, C. Confavreux on behalf of the POPARTMUS Investigators group

50


* Invited lecture


14.00 – 15.30 ImagingChairs: M. Filippi (Milan, IT)

J. Pelletier (Marseille, FR)

14.00 Demyelination and remyelination144* F. Barkhof (Amsterdam, NL)

14.20 Positron emission tomography (PET) and 145* molecular imaging for multiple sclerosis

B. Stankoff, L. Freeman, B. Bodini, L. Bottin, A. Chardain, C. Lubetzki, M. Bottlaender (Paris, Orsay, FR)

14.40 Improved detection of cortical lesions using146 7T magnetisation transfer imaging in patients

with multiple sclerosisR. Abdel-Fahim, N. Mistry, O. Mougin, A. Blazejewska, P. Gowland, N. Evangelou (Nottingham, UK)

14.55 Resting state functional connectivity 147 abnormalities are associated with cognitive

impairment in patients with paediatric multiple sclerosisM. Filippi, M.A. Rocca, P. Valsasina, M.P. Amato, M. Absinta, A. Ghezzi, L. Moiola, A. Fiorino, P. Veggiotti, G. Comi and the MS and Neuroimaging Study Groups of the Italian Neurological Society

15.10 Dynamic changes in grey matter volume over 148 5 years in primary progressive multiple sclerosis:

a tensor-based morphometry studyA. Eshaghi, B. Bodini, G. Ridgway, D. García-Lorenzo, D. Tozer, M.A. Sahraian, A.J. Thompson, O. Ciccarelli (London, UK; Paris, FR; Tehran, IR)

51

Scie

ntifi

c Pr

ogra

mm

e


* Invited lecture


14.00 – 15.30 Disease-modifying treatmentsChairs: G. Comi (Milan, IT)

G. Edan (Rennes, FR)

14.00 Oral treatments: past, present, future149* C.H. Polman (Amsterdam, NL)

14.20 Therapeutic strategies in 2012150* X. Montalban (Barcelona, ES)

14.40 Clinical efficacy of BG-12 in relapsing-remitting151 multiple sclerosis: an integrated analysis

of the phase 3 DEFINE and CONFIRM studiesR. Gold, D. H. Miller, J.T. Phillips, D.L. Arnold, K. Selmaj, M. Yang, R. Zhang, K.T. Dawson, V. Viglietta, S.I. Sheikh, R.J. Fox (Bochum, DE; London, UK; Dallas, Weston, Cleveland, US; Montreal, CA; Lodz, PL)

14.55 Efficacy and safety of ponesimod, an oral,152 selective sphingosine 1-phosphate receptor-1

modulator, in patients with relapsing-remitting multiple sclerosis: results from a phase IIb, randomised, double-blind, placebo-controlled trialT. Olsson, A. Boster, O. Fernandez, M. Freedman, C. Pozzilli, D. Bach, O. Berkani, M. Mueller, T. Sidorenko, M. Melanson (Stockholm, SE; Columbus, Cincinnati, US; Malaga, ES; Ottawa, CA; Rome, IT; Allschwil, CH)

15.10 The efficacy and safety of teriflunomide in153 patients with relapsing MS: results from

TOWER, a phase III, placebo-controlled studyL. Kappos, G. Comi, C. Confavreux, M.S. Freedman, A.E. Miller, T.P. Olsson, J.S. Wolinsky, T. Bagulho, J.-L. Delhay, Y. Zheng, P. Truffinet, P.W. O‘Connor (Basel, CH; Milan, IT; Lyon, Chilly Mazarin, FR; Ottawa, Toronto, CA; New York, Houston, Bridgewater, US; Stockholm, SE)

52


* Invited lecture

Poster Session II Poster Exhibition

15.30 – 17.00 Poster numbers P636 – P1109(for details see pages 108 – 159)

Hot Topic 4 Auditorium Lumière

17.00 – 17.45 Imaging and cognitionChairs: A. Feinstein (Toronto, CA)

F. Fazekas (Graz, AT)

17.00 Morphological imaging154* N. De Stefano (Siena, IT)

17.15 Functional imaging155* C. Enzinger (Graz, AT)

17.30 Relative contribution of thalamus volume and156 diffusion tensor metrics to cognitive impairment in multiple sclerosis

R. Benedict, H.E. Hulst, N. Bergland, M. Schoonheim, M. Dwyer, B. Weinstock-Guttman, J. Geurts, R. Zivadinov (Buffalo, US; Amsterdam, NL)

Hot Topic 5 Forum 2 & 3

17.00 – 17.45 Paediatric MSChairs: M. Tardieu (Paris, FR)

A. Ghezzi (Gallarate, IT)

17.00 The spectrum of paediatric MS and related157* disorders

Y. Mikaeloff (Paris, FR)

17.15 Disease-modifying treatments in paediatric MS158* B. Banwell (Toronto, CA)

17.30 Multiple sclerosis genetic susceptibility factors159 rs4648356 and rs11154801 are associated with

relapse rate in paediatric patientsJ. Graves, L. Barcellos, L. Krupp, A. Belman, E. Waubant (San Francisco, Berkeley, Stony Brook, US)

53


Hot Topic 6 Amphitheatre

17.00 – 17.45 Symptomatic treatmentsChairs: B. Brochet (Bordeaux, FR)

A. Thompson (London, UK)

17.00 Pitfalls in assessing symptomatic treatments160X B. Uitdehaag (Amsterdam, NL)

17.15 Cannabinoids, symptomatic or disease modifying? 161X J.P. Zajicek (Plymouth, UK)

17.30 Walking improvement after deep rTMS with162 H-coil associated with rehabilitation in patients

with progressive multiple sclerosis: a randomised, controlled, double-blind studyL. Leocani, A. Formenti, A. Nuara, P. Rossi, F. Martinelli Boneschi, A. Zangen, M. Comola, G. Comi (Milan, IT)


18.00 – 19.00 Committed to MSorganized by Biogen Idec

Chair: C. Confavreux (Lyon, FR)

18.00 IntroductionC. Confavreux (Lyon, FR)

18.05 Treatment of MS: lessons from real life163 H. Butzkueven (Parkville, AU)

18.20 Targeting the demyelinated axons in MS 164 H.-P. Hartung (Düsseldorf, DE)

18.35 Current treatments and new perspectives for165 MS treatment

D. Miller (London, UK)

18.55 CloseC. Confavreux (Lyon, FR)

19.30 Official Conference Dinner at La Sucrière

Scie

ntifi

c Pr

ogra

mm

e

54

Scientific ProgrammeSaturday, 13 October 2012


08.30 – 10.00 Late Breaking News 2Chairs: L. Kappos (Basel, CH)

P. O‘Connor (Toronto, CA)

08.30 A phase 3 trial to assess the efficacy and166 safety of glatiramer acetate injections 40 mg

administered 3 times a week compared to placeboO. Khan, P. Rieckmann, A. Boyko, K. Selmaj, R. Zivadinov (Detroit, Buffalo, US; Bamberg/Erlangen, DE; Moscow, RU; Lodz, PL)

08.45 Chronic Cerebro-Spinal Venous Insufficiency167 (CCSVI) and global venous haemodynamics in

multiple sclerosis: the CoSMo studyG. Comi, M.A. Battaglia, A. Bertolotto, M. Del Sette, A. Ghezzi, G. Malferrari, M. Salvetti, M. Sormani, E. Stolz, L. Tesio, G.L. Mancardi on behalf of the CoSMo study group

09.00 Positive proof of concept of AIN457, 168 an antibody against interleukin-17A,

in relapsing-remitting multiple sclerosisE. Havrdová, A. Belova, A. Goloborodko, A. Tisserant, I. Jones, H. Garren, D. Johns, AIN457 for MS Study Group

09.15 Primary results of the SELECTION trial of 169 daclizumab HYP in relapsing multiple sclerosis

G. Giovannoni, R. Gold, K. Selmaj, E. Havrdova, X. Montalban, E.-W. Radue, D. Stefoski, M. McNeill, J. Rana, J. Elkins, G. O’Neill (London, Maidenhead, UK; Bochum, DE; Lodz, PL; Prague, CZ; Barcelona, ES; Basel, CH; Chicago, Cambridge, US)

09.30 Natalizumab treatment of progressive170 multiple sclerosis reduces inflammation and

tissue damage – results of a phase 2A proof-of-concept studyJ. Romme Christensen, R. Ratzer, L. Börnsen, E. Garde, M. Lyksborg, H.R. Siebner, T.B. Dyrby, P.S. Sørensen, F. Sellebjerg (Copenhagen, Hvidovre, DK)

55

Scie

ntifi

c Pr

ogra

mm

e

Scientific ProgrammeSaturday, 13 October 2012

* Invited lecture

09.45 Efficacy and safety of oral contraceptives 171 as add-on therapy in patients with

relapsing-remitting multiple sclerosis receiving subcutaneous interferon B-1a: a multicenter, randomized investigator-run clinical trialC. Pozzilli, L. De Giglio, V. Barletta, F. Marinelli, F. De Angelis, V. Gallo, V.A. Pagano, M.A. Bassano, M.C. Piattella, V. Tomassini, P. Pantano (Rome, IT)

10.00 – 10.30 Coffee Break and Poster Viewing

Plenary Session 2 Forum 2 & 3

10.30 – 12.30 Closing SessionChairs: M. Clanet (Toulouse, FR)

C. Confavreux (Lyon, FR)

10.30 Devic’s neuromyelitis optica: What it is, what it172* isn’t and why it’s hard to be sure

B.G. Weinshenker (Rochester, US)

10.50 Treatments highlights173* G. Giovannoni (London, UK)

11.10 Scientific highlights174* A. Ascherio (Boston, US)

11.30 Presentation of selected poster awards, 175 awards for best oral presentations by young

researchers and the MSIF awardM. Clanet (Toulouse, FR) M. Trojano (Bari, IT)

12.25 Welcome to Copenhagen176 P. Soelberg-Sørensen (Copenhagen, DK)

12.30 – 13.00 Lunch

10 – 13 october 2012 lyon, france · 2020-05-06 · scienti c programme scienti c programme...

Documents